Cincinnati, OH – Medpace Core Laboratories, a global full-service core laboratory, and Voximetry, a leader in advanced Radiopharmaceutical Therapy (RPT) dosimetry software and services, today announced a strategic partnership aimed at enhancing radiopharmaceutical clinical trials through the integration of cutting-edge dosimetry technology and comprehensive CRO services.
Through this agreement, Medpace has designated Voximetry as a preferred provider of dosimetry services for its radiopharmaceutical clinical trials. This strategic collaboration builds on a successful working relationship between the two companies since June 2024, during which Voximetry delivered consistent, high-quality dosimetry services supporting Medpace’s global clinical development programs.
“Voximetry’s industry-leading technology, deep domain expertise in advanced dosimetry, and strong commitment to service excellence and regulatory compliance, is what makes them the right partner,” said Scott Holland, Senior Director of Scientific Affairs at Medpace. “Their capabilities enhance our Core Laboratory services by assuring radiopharmaceutical trials include accurate dosimetry with fast turn-around time. For our clients, this will help accelerate development and reduce costs.”
Voximetry’s proprietary software, Torch® Dose Assessment, provides accurate, patient-specific RPT dosimetry by leveraging AI, Monte Carlo algorithms, and high-speed GPU computing from image reconstruction through final dose report. The company’s mission to advance safe, individualized cancer treatment aligns well with Medpace’s goal of driving scientific rigor and operational excellence in clinical trials.
“It is the right time to formalize our partnership with Medpace,” said Sue Wallace, CEO of Voximetry. “Together, we can set a new standard for clinical trial efficiency and excellence from protocol development through analysis of final outcomes.”
Medpace delivers end-to-end clinical trial services including study management, clinical monitoring, regulatory submissions, data management, and more. Its deep therapeutic expertise and disciplined approach accelerate the development of innovative medical treatments.
About Voximetry
Voximetry is committed to enabling personalized and effective theranostic treatment options for patients worldwide through wide-ranging collaboration, deep scientific expertise, and technology-forward progress. Based in Madison, Wisconsin, Voximetry is a Healthtech software and services company pioneering patient-specific radiopharmaceutical treatment planning (RPT) in advanced stage cancer patients.
About Medpace
Headquartered in Cincinnati, Ohio, Medpace employs approximately 5,900 people across 44 countries as of March 31, 2025. Medpace is a scientifically driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages regulatory and therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Medpace Core Laboratories is a component of Medpace Holdings, Inc., the parent company of Medpace Inc.